A Randomized Double-Blind Placebo-Controlled Single Ascending Dose Study to Assess the Safety Tolerability and Pharmacokinetics of C2N-8E12 in Subjects with Progressive Supranuclear Palsy
J
Jared Brosch, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this Phase I study is to see whether a single dose of an experimental drug (meaning a drug that is not approved by the FDA) called C2 N-8E 12 given into your vein (called intravenous or IV) is safe and well-tolerated in subjects with Progressive Supranuclear Palsy (PSP).
Description
The purpose of this study is to see whether a single dose of a drug called C2N-8E12 given to subjects via IV infusion is safe and well-tolerated in subjects with Progressive Supranuclear Palsy.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
progressive supranuclear palsy
-
Age: Between 50 Years - 85 Years
-
Gender: All
Updated on
19 Apr 2024.
Study ID: 1508851609
